Literature DB >> 32098591

Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations.

Malesa Pereira1, Vonetta L Williams2, Julie Hallanger Johnson3, Pablo Valderrabano3,4.   

Abstract

Background: Overdiagnosis is the leading factor contributing to the rapid increase in thyroid cancer incidence of the last decades. During this period, however, thyroid cancer incidence has not been increasing at a constant pace. We hypothesized that changes in the slope of the incidence trends curve, called joinpoints, could be associated with changes in clinical practice guideline recommendations.
Methods: Data were obtained from the initial nine registries of the Surveillance, Epidemiology, and End Results (SEER) Program. Thyroid cancer incidence was analyzed from 1975 to 2016. Joinpoints in thyroid cancer incidence trends and clinical variables were correlated with significant changes in clinical practice recommendations.
Results: Incidence rate trends of medullary and anaplastic thyroid cancer were constant during the study period. Among papillary thyroid cancers (PTCs), three main joinpoints were identified, mainly driven by changes in incidence trends of smaller cancers. First, acceleration followed by two deceleration periods in thyroid cancer incidence coincident in time with the release of American Thyroid Association guidelines in 1996, 2009, and 2015. In 1996, the use of thyroid ultrasound and fine needle aspiration biopsy for the evaluation of thyroid nodules was described; and in 2009 and 2015, higher size thresholds for the biopsy of thyroid nodules were set. For the follicular variant of PTC, a joinpoint was observed around 1988, when the histological diagnosis of this entity was revised in the World Health Organization classification; and another one in 2015 coinciding with the proposal to remove the term carcinoma from noninvasive follicular-pattern tumors with papillary-like nuclear features which contributed to drive down the overall thyroid cancer incidence. Follicular thyroid cancer incidence was affected as well by changes in the guidelines, but to a lesser extent, and it was fairly stable during the study period. Conclusions: This study suggests that thyroid cancer incidence trends have been shaped, in large part, but not completely, by changes in professional guideline recommendations.

Entities:  

Keywords:  SEER; incidence; thyroid cancer subtypes; thyroid carcinoma

Year:  2020        PMID: 32098591     DOI: 10.1089/thy.2019.0415

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  19 in total

1.  Variation in the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features.

Authors:  Debbie W Chen; Farizah I Rob; Rik Mukherjee; Thomas J Giordano; Megan R Haymart; Mousumi Banerjee
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

2.  Prognostic Factors for Excellent Response to Initial Therapy in Patients With Papillary Thyroid Cancer From a Prospective Multicenter Study.

Authors:  Wen-Wu Dong; Da-Lin Zhang; Liang He; Liang Shao; Zhi-Hong Wang; Cheng-Zhou Lv; Ping Zhang; Tao Huang; Hao Zhang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

3.  The Incidence Trend of Papillary Thyroid Carcinoma in the United States During 2003-2017.

Authors:  Yunmei Li; Wenqiang Che; Zhong Yu; Shuai Zheng; Shuping Xie; Chong Chen; Mengmeng Qiao; Jun Lyu
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

Review 4.  Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.

Authors:  Justine A Barletta; Vânia Nosé; Peter M Sadow
Journal:  Endocr Pathol       Date:  2021-01-25       Impact factor: 4.056

5.  Fusion iENA Scholar Study: Sensor-Navigated I-124-PET/US Fusion Imaging versus Conventional Diagnostics for Retrospective Functional Assessment of Thyroid Nodules by Medical Students.

Authors:  Martin Freesmeyer; Thomas Winkens; Luis Weissenrieder; Christian Kühnel; Falk Gühne; Simone Schenke; Robert Drescher; Philipp Seifert
Journal:  Sensors (Basel)       Date:  2020-06-17       Impact factor: 3.576

6.  The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.

Authors:  Inmaculada Isorna; Francisco Esteban; Juan Solanellas; Rafael Coveñas; Miguel Muñoz
Journal:  Eur J Histochem       Date:  2020-04-28       Impact factor: 3.188

7.  Cell competition between anaplastic thyroid cancer and normal thyroid follicular cells exerts reciprocal stress response defining tumor suppressive effects of normal epithelial tissue.

Authors:  Aidana Amrenova; Keiji Suzuki; Vladimir Saenko; Shunichi Yamashita; Norisato Mitsutake
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

8.  Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017.

Authors:  Cari M Kitahara; Julie A Sosa; Meredith S Shiels
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

9.  Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.

Authors:  Cole D Davidson; Eric L Bolf; Noelle E Gillis; Lauren M Cozzens; Jennifer A Tomczak; Frances E Carr
Journal:  J Endocr Soc       Date:  2021-06-01

Review 10.  Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Histol Histopathol       Date:  2020-11-10       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.